CompletedNot Applicable

Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

Mexico90 participantsStarted 2021-11-29

Plain-language summary

Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical practice.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any sex. * Treatment with Sebryl® and / or Sebryl Plus® documented, for at least 2 consultations. * That the patient has been questioned about possible adverse events Exclusion Criteria: * That the patient has used some other concomitant treatment for seborrheic dermatitis and psoriasis on the scalp.

What they're measuring

Proportion of adverse events

Timeframe: Last 5 years

Classify adverse events

Timeframe: Last 5 years

Mean age in years

Timeframe: Last 5 years

Describe study population by gender ratio

Timeframe: Last 5 years

Describe the body mass index through weight and heigh

Timeframe: Last 5 years

Describe the blood pressure millimetres of mercury (mmHg)

Timeframe: Last 5 years

Mean heart rate in beats per minute

Timeframe: Last 5 years

Percentage of times use outside of expected indications

Timeframe: Last 5 years

Trial details

NCT IDNCT05105139

SponsorLaboratorios Silanes S.A. de C.V.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-02-15

View on ClinicalTrials.gov More Seborrheic Dermatitis trials